For Partnership and Advertising , Please email ankit.kankar@mmactiv.com
|
Month |
Content | Country Focus |
| January | 2022: Vision & Mission | Singapore |
| Leveraging investment and expediting innovations in Asian healthcare ecosystem | ||
| Identifying investors & stakeholder opportunities in emerging Asian Bio-pharma market | ||
| Advancing medical devices from bench to bed side and regulatory challenges involved | ||
| Should Bio-pharma companies cooperate for IP protection waiver for propriety medicines during a pandemic? | ||
| Mental Health ventures and crowd funding in Asian countries | ||
| FEBRUARY | APAC seed funding structure and formulations | Japan |
| Point of care (PoC) implementation in APAC and its market potential | ||
| Risk evaluation and management of new drug application (NDA) for novel therapeutic products | ||
| Opportunities, scope and challenges of healthcare biateral trade among APAC countries | ||
| Are health monitoring apps and gadgets overrated? | ||
| Designing appropriate business models at Asian healthcare startup eco system | ||
| March | Women in Asian Healthcare space (Special Edition) | India & SAARC |
| Genomic medicines in the diagnosis and treatment of NCDs | ||
| Prospects and drives in APAC pharmaceutical e-commerce market | ||
| Fine tuning AI devices algorithms for transparancy in medical regulation | ||
| How successful is APAC in attracting western investment to biotechnology and biopharmaceutical sectors? | ||
| Optimum design control and clinical evaluation around medical device life cycle | ||
| April | Precision drug manufacturing and therapeutic innovations in Asia-Pacific | Australia , NZL |
| Incubators and Investor relations in APAC pharma / Bio industry | ||
| Biomarker Testing for Cancer Treatment :: Regulating cancer progression through hormonal and immune therapies | ||
| Navigating through APAC healthcare pricing and reimbursement landscape (Regulatory) | ||
| Will 3D Printing play a reliable role in regenerative medicine? | ||
| Global strategic alliances approach to strengthen Asia’s healthcare ecosystem | ||
| May | Potentials at Asia Pacific active pharmaceutical ingredients (API) market | China |
| CAR-T therapy landscape in bolstering oncology R&D | ||
| Role of Blockchain in streamlining healthcare and supplychain ecosystem | ||
| Implantable medical devices and neurostimulator's market potentials and prospects in APAC | ||
| Can drug repurposing be a solution to reduce the approval cycle of pharma products? | ||
| Implementing Universal Health Coverage (UHC) in Asia’s healthcare landscape (shaping policies and strategic partnership) | ||
| June | Advancements in Drug Delivery Systems (DDS) solutions in APAC | Honkong |
| Aesthetic biomaterial trade and commerce prospects in APAC (surgical bio-cosmetic industry) | ||
| Preventing Adverse Drug Reactions (ADRs) through Pharmacovigilance | ||
| APAC regulatory approval system: Challenges and Opportunities | ||
| Will rapid approval of COVID-19 vaccines pave the path for quick drug approvals in the future? | ||
| Opportunities, scope and challenges of healthcare bilateral trade among APAC countries | ||
| July | Potentials at Asia-Pacific CDMO portfolios and evaluating ideal partnership strategies | South Korea |
| Achieving agility at pharmaceutical R&D and manufacturing sphere | ||
| Promising innovations and technologies to tackle emerging AMR concerns: The APAC response | ||
| Enthralling CRISPR innovations in pioneering therpeutics | ||
| Will healthcare venture capitalisation see a surge in a post-COVID era or will face a pre-pandemic curve? | ||
| Overcoming the side effects of radiation therapy in cancer treatment | ||
| August | 3D cell culture systems: Mimicking human organs and disease models for drug discovery | Taiwan |
| Stem cell banking and potential stem cell treatments in paediatric diagnosis | ||
| Role of next-Gen sequencers and analysers in cutting-edge genomic medicine research | ||
| CMO services in biomanufacturing | ||
| Can novel invitro cell-based approaches replace animal models in drug screenng & evaluation in future? | ||
| Clinical advancements in Diabetes vaccines | ||
| September | Generic drug manufacturing and competitiveness in Asian market | Malaysia & Indonesia |
| Novel trends and innovations in therapeutic medical device sphere | ||
| APAC venture capitalism(VC), investment and funding opportunities in biopharma sector | ||
| Autoimmune disease therapeutics and it's diagnostic market in Asia | ||
| Is medical science having an ethical balance in the cloning/transgenic arena? | ||
| Optimization of venture capitalism and seed-funding in APAC to accelerate RIO | ||
| October | Value addition around strategic sponsorship and market expansion at Asian CRO's | Thailand |
| Strategic valuation models to calculate value of Pharma and Biotech companies (Purchase and selling price evaluation) | ||
| Novel anti-parasitic vaccine development and their market approach (malaria, TB, Dengue, yellow fever) | ||
| Recent 3-D printing revolution in medical devices and diagnostic industry | ||
| Will the growing list of childhood vaccinations interfere with innate immunity genes in future population? | ||
| Implementing universal healthcare coverage | ||
| November | Boosting grants, M&A, capitalism and endowment in Asian healthcare sector | Emerging SEA Countries |
| Latest advancemnets in Pharma and healthcare technology: 2022 trends | ||
| Implementation of platform technologies in drug discovery and vaccine manufacturing | ||
| Internet of Medical Things (IoMT) forecasts for MedTech and HealthTech | ||
| Is APAC successful in shaping Universal Health Coverage (UHC) policies | ||
| Current trend and development in Bioinformatics and Computational Biology | ||
| December | Premier 2022 R&D and revolutionary therapeutic solutions from Asia-Pacific | |
| Role of Microfluidic chip and organ-on-a-chip (OOAC) technology in precision medicine | ||
| Achieving commercial success in APAC pharmaceutical and medical device markets: A survey | ||
| Investigating anti-competitive practices in biosimilar and generics market causing lag in market penetration | ||
| Is telemedicine impactful and reliable with a distant patient examination model? | ||
| Innovative funding models at pharma & biopharmaceutical R&D investments | ||
